Cipla Q4 Results Estimates: How Is The Pharma Giant Expected To Perform Amid US Pressure? 

Synopsis: Cipla is set to announce its Q4FY26 results on May 13, with brokerages expecting near-term pressure from US headwinds while respiratory launches, pipeline expansion, and strong domestic growth remain key factors shaping the company’s broader medium-term outlook. 

Cipla’s board is scheduled to meet on Wednesday, May 13, to consider and approve the company’s audited consolidated and standalone financial results for Q4FY26 and the full financial year ended March 31, 2026. Here are the estimates from Motilal Oswal and ICICI Securities. 

What Are The Expectations?

According to Motilal Oswal and ICICI Securities, Cipla is expected to strengthen its growth outlook through recent USFDA approval for the first AB-rated generic version of Ventolin HFA (albuterol inhaler), providing a first-to-market opportunity in the US respiratory segment. This approval significantly expands Cipla’s high-entry-barrier respiratory portfolio and strengthens its position in complex inhalation products. The product, expected to launch in the first half of FY27 from Cipla’s Fall River facility in the US, is likely to support supply reliability while partially offsetting revenue pressure from declining gRevlimid contribution and Lanreotide discontinuation.

Beyond this, Cipla’s broader pipeline remains a major growth driver, with four respiratory products planned for launch in FY27, including gAdvair and gVentolin, while a broader pipeline of eight respiratory assets, including gSymbicort and gQvar, supports medium-term growth visibility beyond FY27. ICICI Securities also highlights Cipla’s strong India business, supported by branded formulations, consumer wellness, recent Pfizer brand acquisitions, and encouraging traction in newer therapies like tirzepatide. These initiatives are expected to strengthen domestic growth while diversifying revenue streams across multiple therapeutic segments.

While near-term US growth may remain under pressure due to gRevlimid erosion, both brokerages remain positive on Cipla’s medium-term outlook, supported by strong respiratory execution, expanding peptide opportunities, and leadership’s focus on accelerating launches. Key risks remain regulatory delays and rising competition, but Cipla is viewed as well-positioned through portfolio diversification and complex product expansion.

What Are The Estimates?

Motilal Oswal expects Cipla to report revenue of Rs. 6,780 crore in Q4FY26, reflecting a decline of 4.1 percent quarter-on-quarter from Rs. 7,070 crore in Q3FY26, while remaining broadly flat with a marginal increase of 0.7 percent year-on-year compared to Rs. 6,730 crore in Q4FY25.

EBITDA is estimated at Rs. 1,180 crore, which would represent a decline of 6.3 percent sequentially from Rs. 1,260 crore in Q3FY26 and a sharper decline of 23.4 percent year-on-year from Rs. 1,540 crore reported in Q4FY25. EBITDA margins are projected at 17.4 percent.

Net profit is expected to come in at Rs. 830 crore, rising sharply by 22.1 percent quarter-on-quarter from Rs. 680 crore in Q3FY26, but declining by 32 percent year-on-year from Rs. 1,220 crore in Q4FY25. PAT margins are estimated at 12.24 percent.

ICICI Securities projects Cipla’s revenue at Rs. 6,725.9 crore for Q4FY26, indicating a decline of 4.9 percent quarter-on-quarter and a marginal decline of 0.1 percent year-on-year. EBITDA is estimated at Rs. 1,087.3 crore, which implies a decline of 13.7 percent sequentially and a 29.4 percent decline year-on-year. EBITDA margins are expected at 16 percent.

Net profit is projected at Rs. 743.5 crore, reflecting an increase of 9.3 percent quarter-on-quarter, while declining by 39.1 percent year-on-year. PAT margins are estimated at 11 percent.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Cipla Q4 Results Estimates: How Is The Pharma Giant Expected To Perform Amid US Pressure?  appeared first on Trade Brains.